Rebecca Araujo

DocwireNews

A study published in <a href="https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2020008787/475589/Oral-ixazomib-lenalidomide-and-dexamethasone-for?redirectedFrom=fulltext">Blood</a> evaluated outcomes of oral ixazomib with lenalidomide plus dexamethasone for the treatment of patients with newly diagnosed, transplant-ineligible multiple myeloma (MM).The TOURMALINE-MM2 trial was a double-blind, placebo-controlled study of 706 patients with newly diagnosed, transplant-ineligible MM. Participants were randomized to a regimen of lenalidomide plus dexamethasone with or without ixazomib 4 mg. Overall, 351 patients received the ixazomib combination and 354 received a placebo. After 18 cycles, dexamethasone use was discontinued. The experimental cohort then received continued treatment with reduced dose ixazomib plus lenalidomide (3 mg and 10 mg, respectively) until disease progression or unacceptable toxicity. The study&rsquo;s primary endpoint was progression free survival (PFS).The addition of ixazomib spurred a non-statistically significant increase in PFS. The median PFS for the experimental group was 35.3 months, compared with 21.8 months in the placebo group (hazard ratio [HR] 0.83; 95% confidence interval [CI] 0.676-1.018; P = 0.73). In the ixazomib group, 26% of patients achieved a complete response and 63% achieved a very good partial response or better, compared with 14% and 48% of the placebo group, respectively (P &lt; 0.001). Among patients with high-risk MM, median PFS was 23.8 months for ixazomib versus 18.0 months for the placebo (HR 0.69; P = 0.019).Grade 3 or higher treatment-related adverse events (AEs) occurred in 88% and 81% of patients in the experimental versus control groups. Mortality on study occurred in 8% of patients in the ixazomib group and 6% of patients in the placebo group.In conclusion, the researchers wrote, &ldquo;TOURMALINE-MM2 demonstrates that ixazomib [with lenalidomide plus dexamethasone] is a feasible treatment option for certain transplant-ineligible patients with newly diagnosed MM who could benefit from an all-oral triplet regimen.&rdquo;<blockquote class="twitter-tweet">
In the TOURMALINE-MM2 trial, the addition of ixazomib to Rd for non-transplant eligible NDMM caused only a non-significant increase in PFS (HR 0.830, p = 0.073), although the mPFS (35.3 vs 21.8 months) and response rates (63% vs 48%) were improved: <a href="https://t.co/Xyy6IM03O9">https://t.co/Xyy6IM03O9</a> <a href="https://twitter.com/hashtag/MMSM?src=hash&amp;ref_src=twsrc%5Etfw">#MMSM</a>
&mdash; NatureRevClinOncol (@NatRevClinOncol) <a href="https://twitter.com/NatRevClinOncol/status/1377614223493066753?ref_src=twsrc%5Etfw">April 1, 2021</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script><blockquote class="twitter-tweet">
Richard Labotka, MD, hematologist-oncologist at the University of Illinois Hospital talks about the latest results from the TOURMALINE-MM2 study presented at <a href="https://twitter.com/hashtag/ASH2020?src=hash&amp;ref_src=twsrc%5Etfw">#ASH2020</a>.<a href="https://t.co/gi8LOkz9Gr">https://t.co/gi8LOkz9Gr</a><a href="https://twitter.com/theMMRF?ref_src=twsrc%5Etfw">@theMMRF</a> <a href="https://twitter.com/TakedaPharma?ref_src=twsrc%5Etfw">@TakedaPharma</a> 
Multiple Myeloma Research Foundation &ndash; MMRF 
Takeda
&mdash; CheckRare (@CheckRare) <a href="https://twitter.com/CheckRare/status/1370381732143333382?ref_src=twsrc%5Etfw">March 12, 2021</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

TOURMALINE-MM2: Oral Ixazomib Combo for Transplant-Ineligible Multiple Myeloma

Oncology

A study published in Blood evaluated outcomes of oral ixazomib with lenalidomide plus dexamethasone for the treatment of patients with newly diagnosed, transplant-ineligible ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe